Finishing Osteomyelitis Without a Line to Protect
Neither of the usual ways to finish his antibiotic course is safe for him the way it would be for most patients. The evidence for the alternative is thinner — but so is his real chance of completing either standard option.
Corey L., a 36-year-old man with an active opioid use disorder currently not engaged in medication treatment, was admitted three weeks ago with MSSA osteomyelitis of the left tibia following a skin infection at an injection site, and has completed initial IV nafcillin therapy inpatient with good clinical response — decreasing pain, improving inflammatory markers, and a repeat MRI showing early healing. He needs several more weeks of therapy to complete an adequate course, and the standard options — outpatient IV therapy through a PICC line, or an extended oral regimen — both carry real, specific risks for him that they wouldn’t carry for most other patients being discharged with the same diagnosis.
A PICC line, if he continues using intravenously, is a well-recognized route for line misuse and a genuine catheter-related infection risk, not a hypothetical concern raised reflexively about anyone with a substance use history — he has had a prior hospitalization for exactly this complication two years ago. Oral therapy avoids the line risk but depends on daily adherence over several more weeks, complicated by housing that has been unstable since he lost his apartment last spring. He has expressed interest in reducing his substance use but is not currently connected to treatment, and the team is weighing whether a long-acting injectable antibiotic, requiring only two clinic visits rather than either daily pills or an indwelling line, is a better match for his actual circumstances than either conventional completion strategy.
What makes dalbavancin mechanistically suited to this particular gap is its unusually long terminal half-life, on the order of two weeks, which lets a single dose maintain therapeutic drug levels for the interval a shorter-acting agent would need daily or near-daily dosing to sustain — the same glycopeptide-class cell-wall disruption as vancomycin, just packaged into a pharmacokinetic profile built for exactly the adherence gap his situation creates. That profile is also precisely why the drug’s evidence base for this specific indication remains thinner than his team would prefer: the extended-interval dosing that makes it attractive here is a relatively recent development, and osteomyelitis completion rests largely on Rappo et al.’s single open-label two-dose study and observational series rather than the randomized comparisons that support skin and soft-tissue infection, its original and best-studied indication.
Discharge planning, infectious disease and addiction medicine
I want to use dalbavancin to complete his course — two doses, one week apart, and he’s done. He has a documented prior line infection from exactly this scenario, so a PICC isn’t a theoretical risk for him, it’s a repeat of something that already happened. Daily oral therapy has its own real adherence risk given his housing situation. A long-acting agent removes both vulnerabilities at once rather than trading one for the other.
I want to flag honestly that dalbavancin doesn’t have the same depth of controlled-trial evidence for osteomyelitis that OPAT and oral step-down both have — Rappo et al. is a single open-label study, and most of the rest is observational, and this is an off-label use. Reaching for an unconventional route because the conventional ones are complicated by his substance use is understandable, but I don’t want us to undertreat him because the real-world evidence turns out thinner than the observational data suggests.
I think the comparison you’re making is against an idealized OPAT or oral course, not the one actually achievable for him. Realistically, given his housing and his history, his odds of completing either conventional option safely and on schedule are genuinely lower than for most patients discharged with this diagnosis. Against THAT real comparison — not a hypothetical ideal one — I think the evidence gap you’re naming is a smaller concern than the completion-rate and line-safety gap the other two routes actually carry for him specifically.
Agreed: complete his course with two doses of dalbavancin, one week apart, with the second dose visit also used as a scheduled touchpoint to connect him with addiction medicine services given his expressed interest.
Also agreed, separately: this decision was documented explicitly as specific to his circumstances — the stewardship pharmacist’s evidence-quality concern remains on record and was not treated as resolved in general, only outweighed for this particular patient’s realistic alternatives.